Sort
15,273 grants matching “antimicrobial resistance”
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
$1,171,930Ashraf S. Ibrahim · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · R01 · FY2020 · AI
Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea
$1,170,759Sanjay Ram · Univ Of Massachusetts Med Sch Worcester · R01 · FY2020 · AI
REDUCING UNNECESSARY ANTIMICROBIAL USE (AMU) ON LIVESTOCK FARMS HAS LONG BEEN ADVOCATED TO MITIGATE ANTIMICROBIAL RESISTANCE. VETERINARIANS PRESCRIBE AND DISPENSE ANTIMICROBIALS, BUT FARM WORKERS ARE NECESSARILY RESPONSIBLE FOR INITIATING ANTIMICROBIAL THERAPY, AND RELY ON OBSERVABLE CLINICAL SIGNS AND THE JUDGEMENT OF DISEASE SEVERITY TO MAKE TREATMENT DECISIONS. UNNECESSARY AMU MAY NEGATIVELY IMPACT PUBLIC HEALTH; HOWEVER, WITHHOLDING EFFECTIVE ANTIMICROBIAL THERAPY OR NEGLECTING TREATABLE INFECTIONS WOULD COMPROMISE ANIMAL HEALTH AND WELFARE. SOCIETY HAS PLACED SUBSTANTIAL RESPONSIBILITY ON THE SHOULDERS OF FARM WORKERS, WHO ARE TASKED WITH BOTH COMPLETE IDENTIFICATION OF ANIMALS REQUIRING THERAPY, AND THE PROTECTION OF PUBLIC HEALTH BY MINIMIZING UNNECESSARY AMU. THEREFORE, THERE IS A CRITICAL NEED TO DEVISE FARM WORKER DIRECTED ANTIMICROBIAL STEWARDSHIP EDUCATION TO REDUCE UNNECESSARY ANTIMICROBIAL USE. OUR OVERALL GOAL IS TO REDUCE THE CONSUMPTION OF ANTIMICROBIALS ON DAIRY FARMS WHILE MAINTAINING ANIMAL HEALTH AND PRODUCER PROFITABILITY. SUSTAINED EFFORTS ON ANTIMICROBIAL STEWARDSHIP WILL REQUIRE BEHAVIORAL CHANGES WITHIN DAIRY FARM PERSONNEL. THEREFORE, WE HYPOTHESIZE THAT ANTIMICROBIAL STEWARDSHIP (AMS) EDUCATION TARGETING FARM WORKERS WILL CHANGE PRODUCER ATTITUDES, REDUCE QUANTIFIED AMU, MAINTAIN PROFITABILITY, AND ALTER THE FARM ANTIMICROBIAL RESISTOME. FIRST, WE'LL USE A HIERARCHICAL SURVEY TO IDENTIFY INFLUENCERS AND BARRIERS TOWARDS IMPROVED AMS PRACTICES AT THE VETERINARIAN AND PRODUCER LEVELS. THE SURVEY WILL COLLECT FARM WORKER DISEASE SEVERITY TREATMENT THRESHOLDS, AND WE'LL PROVIDE A QUANTITATIVE ESTIMATE OF THE POTENTIAL FOR REDUCTIONS IN ANTIMICROBIALS USED FOR TREATMENT. LASTLY, WE'LL DEVELOP AND IMPLEMENT FARM WORKER ORIENTED ANTIMICROBIAL STEWARDSHIP EDUCATION MATERIALS, AND USE A LONGITUDINAL, FARM-LEVEL STUDY TO TEST THE IMPACT OF THE EDUCATIONAL INTERVENTION ON CHANGES IN WORKER ATTITUDES, QUANTIFIED AMU, AND THE FARM ANTIMICROBIAL RESISTOME. THE RESULTS OF THESE RESEARCH AIMS WILL BE CRITICAL FOR THE EVIDENCE-BASED CREATION OF COMPREHENSIVE STEWARDSHIP PROGRAMS ON DAIRY FARMS.
$1,168,156Ohio State University, The · · FY2018 · National Institute of Food and Agriculture
Rapid multiplex method for direct phenotypic ID/AST of bacterial pathogens
$1,168,045Ian Fleming · Guild Associates, Inc. · R01 · FY2020 · AI
FilmArray Direct: Rapid Diagnosis of Antimicrobial-Resistant Pathogens from Blood
$1,166,103Andrew Hemmert · Biofire Diagnostics, Llc · R01 · FY2019 · AI
Rapid multiplex method for direct phenotypic ID/AST of bacterial pathogens
$1,158,336Natasha Jayna Sharp · Guild Associates, Inc. · R01 · FY2021 · AI
CONTROL OF PERIODONTAL INFECTIONS
$1,158,142Forsyth Institute · P01 · FY2002 · DE
A multiscale approach to develop and apply fluoride efflux inhibitors to reverse oral dysbiosis and eliminate early childhood caries
$1,157,291Randy B. Stockbridge · University Of Michigan At Ann Arbor · RM1 · FY2024 · DE
Early Antipseudomonal Therapy in Cystic Fibrosis
$1,155,162Bonnie W Ramsey · Seattle Children'S Hospital · U01 · FY2008 · HL
Consortium for drug-resistant Gram-negative pathogen detection
$1,154,056Lee W Riley · University Of California Berkeley · R01 · FY2015 · AI
Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection
$1,153,277David B. Weiner · Wistar Institute · R01 · FY2020 · AI
Xenobiotic Receptors
$1,152,410Frank J Gonzalez · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
$1,151,780Ashraf S. Ibrahim · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · R01 · FY2023 · AI
Broad-Spectrum Antimicrobials Targeting the D-Alanine Pathway
$1,151,358Karen G. Anthony · L2 Diagnostics, Llc · U01 · FY2009 · AI
Ultrarapid culture-independent detection of high-priority carbepenem resistant Enterobacteriaceae directly from blood
$1,150,815Connie Savor Price · Denver Health And Hospital Authority · R01 · FY2015 · AI
Task V28: Process Development and Master Bank Production for a Staph aureus Vaccine Candidate
$1,149,011Andreas Neubert · Idt Biologika Gmbh · N01 · FY2021 · AI
TO ACHIEVE MANY OF THE GOALS OF NASA S AND ESA S SPACE PROGRAMS REQUIRES AN ENDURING HUMAN PRESENCE IN SPACE. LONG TERM HUMAN MISSIONS REQUIRE SUSTAINED CREW HEALTH AND SAFETY. A RESEARCH AREA THAT IS IMPORTANT IN SUSTAINING CREW HEALTH IS THE DEVELOPMENT OF IMPROVED SPACEFLIGHT-SUITABLE METHODS FOR MICROBIOLOGICAL MONITORING AS WELL AS CONTAMINATION CONTROL AND REDUCTION. THE INTERNATIONAL SPACE STATION (ISS) IS A CONFINED AND ISOLATED HABITAT IN AN EXTREME HOSTILE ENVIRONMENT. THE HUMAN AND HABITAT MICROFLORA VARIES IN RESPONSE TO CHANGES IN ENVIRONMENTAL CONDITIONS ABOARD THE ISS. CHANGES IN THE MICROFLORA MAY RESULT IN AN INCREASED HEALTH RISK FOR THE CREW. MICROORGANISMS INCLUDING MICROBIAL BIOFILMS HAVE BEEN FOUND ON VARIOUS HABITAT SURFACES INSIDE THE AIR AND WATER HANDLING SYSTEMS AS WELL AS THE HARDWARE USED ON THE ISS. BIOFILMS ARE KNOWN TO CAUSE DAMAGE TO EQUIPMENT FROM POLYMER DETERIORATION METAL CORROSION AND BIO-FOULING. THE PRIMARY CONCERN REGARDING CREW HEALTH IS CHARACTERIZED BY ACTIVITY OF OPPORTUNISTIC PATHOGENIC MICROORGANISMS THAT HAVE BEEN NOTED TO ACCUMULATE IN THE CLOSED ENVIRONMENTS OF THE ISS AND OTHER SPACECRAFT ON LONG-DURATION MISSIONS. UNDERSTANDING THE EFFECTS OF THE SPACE ENVIRONMENT ESPECIALLY ALTERED GRAVITY ON MICROBIAL BIOFILMS IS CRUCIAL FOR THE SUCCESS OF LONG-TERM HUMAN SPACE MISSIONS. SURFACE-ASSOCIATED BIOFILM COMMUNITIES WERE ABUNDANT ON THE MIR SPACE STATION AND CONTINUE TO BE A CHALLENGE ON THE ISS. THE HEALTH AND SAFETY HAZARDS LINKED TO THE DEVELOPMENT OF BIOFILMS ARE OF PARTICULAR CONCERN DUE TO THE SUPPRESSION OF HUMAN IMMUNE FUNCTION OBSERVED DURING SPACEFLIGHT. VARIOUS STUDIES HAVE SHOWN THAT CERTAIN METALS REDUCE THE NUMBER OF CONTACT-MEDIATED MICROBIAL INFECTIONS. ANTIMICROBIAL SURFACES ARE DEFINED AS MATERIALS THAT CONTAIN AN ANTIMICROBIAL AGENT SUCH AS SILVER COPPER AND THEIR ALLOYS THAT INHIBITS OR REDUCES THE ABILITY OF MICROORGANISMS TO GROW ON THE SURFACE OF A MATERIAL. ANTIMICROBIAL SURFACES ARE FUNCTIONALIZED IN A VARIETY OF DIFFERENT PROCESSES. THE INTRODUCTION OF ANTIMICROBIAL SURFACES FOR MEDICAL PHARMACEUTICAL AND INDUSTRIAL PURPOSES HAS SHOWN THEIR UNIQUE POTENTIAL FOR REDUCING AND PREVENTING MICROBIAL CONTAMINATION. THE CONTACT KILLING OF SEVERAL TYPES OF MICROORGANISMS BY COPPER HAS BEEN ASSESSED IN MULTIPLE LABORATORY INVITRO STUDIES. FOR SUSTAINED CREW HEALTH AND SAFETY ADDITIONAL STUDIES ON THE MECHANISMS INVOLVED IN THE FORMATION OF MICROBIAL BIOFILMS AND THEIR EFFICIENT DESTRUCTION UNDER SPACEFLIGHT CONDITIONS I.E. LONG-TERM GROWTH AND ADAPTATION TO LOW GRAVITY ENVIRONMENTS ARE NEEDED. THE HYPOTHESIS TO BE TESTED BY METALLICA IS THAT SURFACES CONTAINING COPPER AND/OR SILVER WILL INHIBIT BIOFILM FORMATION UNDER ALTERED GRAVITY REGIMES TO A LESSER EXTENT THAN IN 1 X G DUE TO THE FACT THAT THE INTERACTION WITH THE METAL IONS ON THE SURFACE IS SLOWER BECAUSE THEIR MOVEMENT AROUND THE CELL IS RESTRICTED TO DIFFUSION. THE OBJECTIVE IS TO DETERMINE THE EFFECT AND THE RATE IF ANY OF COPPER AND/OR SILVER SURFACES ON MICROBIAL GROWTH RATE TOTAL BIOMASS ACCUMULATION AND BIOFILM FORMATION. THE GOAL IS TO DEVELOP A CONCEPTUAL MODEL DESCRIBING THE AFFECT OF MICRO-GRAVITY ON BIOFILM FORMATION GROWN ON NON-INHIBITING SURFACES AS WELL AS ON METAL SURFACES THAT ARE POTENTIAL BIOFILM GROWTH INHIBITORS. THE APPROACH WILL BE TO TEST THREE DIFFERENT MICROBIAL MODEL SYSTEMS (I.E. ESCHERICHIA COLI K12 A STAPHYLOCOCCUS SP. ISOLATE FROM THE ISS AND THE HEAVY METAL RESISTANT STRAIN CUPRIAVIDUS METALLIDURANS CH34) FOR BIOFILM FORMATION ON VARIOUS COPPER- AND SILVER-SURFACES AS WELL AS INERT SURFACES AS CONTROLS. THESE SURFACES DIFFER IN THEIR ANTIMICROBIAL ACTIVITY BASED ON CHEMICAL COMPOSITION AND/OR GEOMETRIC NANOSTRUCTURES. THESE SURFACES WILL BE TESTED FOR BIOFILM FORMATION RATES UNDER DIFFERENT SPACEFLIGHT RELEVANT GRAVITATIONAL REGIMES (E.G. MOON 0.16 X G MARS 0.38 X G G ISS AND 1 X G CONTROL). MICROBIAL GROWTH WILL OCCUR UNDER OPTIMAL BIOFILM-INDUCING CON
$1,148,591Bay Area Environmental Research Institute · · FY2020 · National Aeronautics and Space Administration
Combatting AntiMicrobial Resistance in Africa Using Data Science (CAMRA)
$1,145,916Christian T. Happi · Redeemer'S University · U54 · FY2021 · TW
Identification of novel MDR antimicrobials from insect-Streptomyces symbioses
$1,142,106Cameron Robert Currie · University Of Wisconsin-Madison · U19 · FY2020 · AI
Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens
$1,142,038David S Perlin · Hackensack University Medical Center · R01 · FY2022 · AI
Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens
$1,142,038David S Perlin · Hackensack University Medical Center · R01 · FY2023 · AI
Discovering antimicrobials acting against MDR pathogens
$1,141,522Kim Lewis · Northeastern University · R01 · FY2023 · AI
CAREER: Unraveling the metabolic interface between pathogenic Pseudomonas syringae bacteria and host plants
$1,139,270Jeffrey C Anderson · Oregon State University · · FY2020 · BIO
Vaccine and Treatment Evaluation Units
$1,137,245Nadine Georges Rouphael · Emory University · UM1 · FY2024 · AI
Clinical Development and Evaluation of a Deep Learning Approach to Improve Diagnostic Accuracy
$1,136,886Ryan L Shelton · Photonicare, Inc. · R44 · FY2020 · DC